Company intelligence / Profile preview

Meroven

Dublin, Irelandmeroven.com ↗
Ownership
Private
Development stage
Other
01

Overview

Meroven markets generic pharmaceuticals, OTC products, and healthcare items including Mer-418™ for CML and partnerships for Ibalizumab-UIYK (Trogarzo®) for HIV.

Therapeutic areas
HematologyInfectious Diseases
Modalities
Small moleculeMonoclonal antibody
Industry
Biotech
02

Drug pipeline

3 assets

Mer-418

Preclinical

2 more assets in the full pipeline.

03

Partnerships

CURE PharmaceuticalTaiMed BiologicsTheratechnologies, Inc.Biogen, Inc.Reyoung Pharmaceutical Co. Ltd.

Beyond the preview

Go deeper on Meroven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meroven.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call